Vimarsana
Biggest News Aggregation in the World

Page 28 - Eva Mathews News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Eva Mathews. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Eva Mathews Today - Breaking & Trending Today

UK recruiter Robert Walters expects profit in line with market view - Vimarsana News

UK recruiter Robert Walters expects profit in line with market view

Robert Walters on Thursday forecast its full-year pretax profit to be in line with market expectations even as the British recruiter reported a drop in its quarterly net fees amid a tough hiring... -January 11, 2024 at 02:31 am EST - MarketScreener

UK's Ofgem fines Shell Energy UK 1 pound after overcharging probe - Vimarsana News

UK's Ofgem fines Shell Energy UK 1 pound after overcharging probe

Britain's energy regulator Ofgem on Wednesday imposed a 1 pound fine on Shell Energy UK, formerly known as Hudson Energy Supply UK, following a probe into the company overcharging its customers. ... -January 10, 2024 at 05:24 am EST - MarketScreener

UK's Pennon buys owner of Sutton and East Surrey Water in $482 mln deal - Vimarsana News

UK's Pennon buys owner of Sutton and East Surrey Water in $482 mln deal

British water company Pennon Group on Wednesday acquired the holding company of Sutton and East Surrey Water for an enterprise value of 380 million pounds , in a bid to expand its foothold...

GSK to acquire Aiolos Bio in $1.4 bln deal - Vimarsana News

GSK to acquire Aiolos Bio in $1.4 bln deal

British drugmaker GSK on Tuesday said it would acquire clinical-stage biopharmaceutical firm Aiolos Bio for a $1 billion upfront payment and up to $400 million in certain success-based regulatory...

GSK to acquire Aiolos Bio in $1.4 billion deal - Vimarsana News

GSK to acquire Aiolos Bio in $1.4 billion deal

Founded in 2023, Aiolos is focused on developing therapies for respiratory and inflammatory conditions. It is currently developing 'AIO-001', a treatment for asthma which is ready to enter mid-stage clinical trials. The drug would expand the reach of its current respiratory biologics portfolio, including to the 40% of severe asthma patients with certain conditions, where treatment options are still needed, said Tony Wood, GSK's chief scientific officer.

Source: yahoo.com